Compare Abeona Therapeutics Inc (ABEO) vs Msci Inc (MSCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Msci Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Msci Inc trades at $603.1 (market cap $44.27B). The key difference: Msci Inc is far larger — about 118.6× Abeona Therapeutics Inc's market cap, and Msci Inc pays a 1.35% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MSCI | |
|---|---|---|
Market Cap | $373.32M | $44.27B |
Sector | Health | Financials |
52-Week High | $7.23 | $643.83 |
52-Week Low | $4.17 | $511.84 |
Enterprise Value | $228.22M | $50.43B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MSCI trades at $608.09, up 0.83% with a bullish technical outlook and strong fundamental performance. The company delivered three consecutive quarterly earnings beats, maintains exceptional profit margins above 40%, and shows consistent revenue growth. Recent strategic acquisitions and AI integration initiatives position MSCI for continued market leadership in financial analytics and index services.
With 69% analyst buy ratings and a $700.50 consensus price target representing 15% upside, MSCI offers growth potential despite premium valuations. Key risks include high debt levels and market classification decisions impacting revenue streams. The stock's current technical setup near pivot point $606 suggests potential for continued upward momentum if earnings momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
